189 related articles for article (PubMed ID: 33377985)
1. Heart and kidney disease: a cardiovascular high-risk constellation.
Schunk SJ; Speer T; Fliser D
Herz; 2021 Jun; 46(3):206-211. PubMed ID: 33377985
[TBL] [Abstract][Full Text] [Related]
2. [Chronic kidney disease-a cardiovascular high-risk constellation].
Speer T; Schunk SJ; Fliser D
Internist (Berl); 2020 Apr; 61(4):340-348. PubMed ID: 31578597
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular disease and its relationship with chronic kidney disease.
Liu M; Li XC; Lu L; Cao Y; Sun RR; Chen S; Zhang PY
Eur Rev Med Pharmacol Sci; 2014 Oct; 18(19):2918-26. PubMed ID: 25339487
[TBL] [Abstract][Full Text] [Related]
4. [Chronic kidney disease (CKD) as an independent risk factor for cardiovascular disease (CVD)].
Minami J; Ishimitsu T; Sudo Y; Matsuoka H
Nihon Rinsho; 2008 Sep; 66(9):1657-63. PubMed ID: 18788391
[TBL] [Abstract][Full Text] [Related]
5. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
[TBL] [Abstract][Full Text] [Related]
6. Arterial location-specific calcification at the carotid artery and aortic arch for chronic kidney disease, diabetes mellitus, hypertension, and dyslipidemia.
Yamada S; Oshima M; Watanabe Y; Miyake H
Calcif Tissue Int; 2014 Sep; 95(3):267-74. PubMed ID: 25017195
[TBL] [Abstract][Full Text] [Related]
7. Arterial stiffness and increased cardiovascular risk in chronic kidney disease.
Ma Y; Zhou L; Dong J; Zhang X; Yan S
Int Urol Nephrol; 2015 Jul; 47(7):1157-64. PubMed ID: 25991557
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular disease in chronic kidney disease: risk factors, pathogenesis, and prevention.
Ardhanari S; Alpert MA; Aggarwal K
Adv Perit Dial; 2014; 30():40-53. PubMed ID: 25338421
[TBL] [Abstract][Full Text] [Related]
9. Increased cardiovascular risk in patients with chronic kidney disease.
Vondenhoff S; Schunk SJ; Noels H
Herz; 2024 Mar; 49(2):95-104. PubMed ID: 38416185
[TBL] [Abstract][Full Text] [Related]
10. Association of Zinc Deficiency with Development of CVD Events in Patients with CKD.
Nakatani S; Mori K; Shoji T; Emoto M
Nutrients; 2021 May; 13(5):. PubMed ID: 34063377
[TBL] [Abstract][Full Text] [Related]
11. Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy.
Athyros VG; Tziomalos K; Karagiannis A
Expert Rev Cardiovasc Ther; 2015; 13(9):1059-66. PubMed ID: 26206619
[TBL] [Abstract][Full Text] [Related]
12. Dyslipidemia in chronic kidney disease: are statins still indicated in reduction cardiovascular risk in patients on dialysis treatment?
Scarpioni R; Ricardi M; Melfa L; Cristinelli L
Cardiovasc Ther; 2010 Dec; 28(6):361-8. PubMed ID: 20553296
[TBL] [Abstract][Full Text] [Related]
13. The MAURO study: baseline characteristics and compliance with guidelines targets.
Leonardis D; Mallamaci F; Enia G; Postorino M; Tripepi G; Zoccali C;
J Nephrol; 2012; 25(6):1081-90. PubMed ID: 23172127
[TBL] [Abstract][Full Text] [Related]
14. [USE OF STATINS IN PATIENTS WITH CHRONIC KIDNEY DISEASE TO PREVENT CARDIOVASCULAR DISEASE].
Zavidić T; Lodeta B; Lovrinić Đ
Acta Med Croatica; 2016 Dec; 70(4-5):301-7. PubMed ID: 29087163
[TBL] [Abstract][Full Text] [Related]
15. Chronic kidney disease as a cardiovascular risk factor.
Carmena R; Ascaso JF; Redon J
J Hypertens; 2020 Nov; 38(11):2110-2121. PubMed ID: 32649622
[TBL] [Abstract][Full Text] [Related]
16. Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
Fruchart JC; Hermans MP; Fruchart-Najib J
Curr Atheroscler Rep; 2020 Jul; 22(8):43. PubMed ID: 32671476
[TBL] [Abstract][Full Text] [Related]
17. Impact of Chronic Kidney Disease on Risk for Vascular Events.
Fan J; Salameh H
Curr Vasc Pharmacol; 2016; 14(5):409-414. PubMed ID: 27456102
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risk stratification in primary care patients with arterial hypertension: Results from the Swiss Hypertension Cohort Study (HccH).
Handschin A; Brighenti-Zogg S; Mundwiler J; Giezendanner S; Gregoriano C; Martina B; Tschudi P; Leuppi JD; Zeller A; Dieterle T
Eur J Prev Cardiol; 2019 Nov; 26(17):1843-1851. PubMed ID: 31189378
[TBL] [Abstract][Full Text] [Related]
19. Pediatric CKD and cardiovascular disease.
Safder O; Al sharif S; Kari JA
Cardiovasc Hematol Disord Drug Targets; 2014; 14(3):177-84. PubMed ID: 24720458
[TBL] [Abstract][Full Text] [Related]
20. The impact of antihypertensive pharmacotherapy on interplay between protein-bound uremic toxin (indoxyl sulfate) and markers of inflammation in patients with chronic kidney disease.
Kaminski TW; Pawlak K; Karbowska M; Znorko B; Mor AL; Mysliwiec M; Pawlak D
Int Urol Nephrol; 2019 Mar; 51(3):491-502. PubMed ID: 30617956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
